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Effectiveness of EpiPen and Its Alternatives
Emma Sanford & Rebecca Anderson

Abstract
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Evaluation & Analysis

The purpose of this project was to compare the effectiveness of the
EpiPen and its alternatives. Epipens are the first-line treatment for
systemic allergic reactions. The pharmaceutical company Mylan first
came into existence in 1961, distributing medical and health products to
medical professionals with the goal of providing access to affordable
medicine. Epipens now-a-days can cost anywhere from $650-$700, while
alternatives like Symjepi cost around $200, Adrenaclick is about $500
and Auvi- Q is around $5,000 for a twin pack but can be free with
insurance. For this project we looked at various different sources about
each brand. From those sources we compared the information gathered
and based the conclusion off of the sources that were all 5 years or
younger. We looked at pricing and insurance, price trends, and the
differences of each epinephrine auto-injector. It was concluded that the
cheaper alternatives are equally as effective as Epipen.

EpiPens cost about $600 or more for a twin pack and a trainer
device. Some insurance companies cover the whole cost of the Epipen.
Other companies negotiate the price on how much they are willing to
take off (Cleveland Clinic, 2019). When looking for alternatives for
EpiPens it is found that Auvi- Q is around $5,000 for a twin pack
(Anderson, L., 2020). However, it can be free for anyone with
commercial insurance. It is also available for mail-order pharmacy
(Cleveland Clinic, 2019). Another alternative, Adrenaclick, is only $100
less than the EpiPens, making it $500 for the twin pack. However, a
more affordable generic version can be found at CVS for about $110
(Cleveland Clinic, 2019). Figure.1 shows a comparison between generic
EpiPen and Adrenaclick and their price trends from 2014-2018
(GoodRx, 2018). Lastly, Symjepi is a newer prescription epinephrine
device. It costs about $240-$280 for a twin pack (Anderson, L., 2020).
For Symjepi it does not look like there is any insurance coverage. In the
articles found it was based solely on price, it did not mention if any one
worked better or worse than an EpiPen.
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Introduction
Epinephrine is the first-line treatment for systemic allergic
reactions, however, epinephrine autoinjectors are expensive and
availability is limited. The pharmaceutical company Mylan first
came into existence in 1961, distributing medical and health
products to medical professionals with the goal of providing access
to affordable medicine. Mylan has now grown into a company with
more than 7,500 different products. Sheldon Kaplan designed the
Epipen in 1980 for Survival Technology, Inc. (National Inventors
Hall of Fame, 2016). In 2007 Mylan bought the rights to Epipen,
and the price has since risen from $57 to $600 or more (Cuollo,
2018, p. 265). In an article by Adam Rubenfire (2016), the cost for
one Epipen injector in 1986 was around $36 (Rubenfire, 2016).
There are cheaper generic epinephrine autoinjectors available on
the market now that have been found to be as effective as the
name brand Epipen.

Figure. 1

It can be concluded that Epinephrine products cannot be used as a
prophylactic. It is used as an emergency medication. In terms of
alternatives to the EpiPen they are less expensive. However, the
alternatives are not any better or worse than an EpiPen. The main
difference between all of them is that some have a trainer device and
others don’t. Ultimately, the alternatives are good for saving money and
will work just as well as the name brand EpiPen. For future research a
study could be done that focuses only on how effective the alternatives
are.

Methods
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For this project we looked at articles that talked about the price of
EpiPens. From those articles we found what possible alternatives could
be. Finding out the alternatives allowed us to narrow our search and
compare 2-3 different types of alternatives, Auvi-Q, Adrenaclick, and
Symjepi. For this project we looked at articles that talked about the
price of EpiPens. From those articles we found what possible
alternatives could be. Finding out the alternatives allowed us to narrow
our search and compare 2-3 different types of alternatives, Auvi-Q,
Adrenaclick, and Symjepi. We compared, price and insurance, price
trends, and the differences between each alternative.

Conclusion & Implications for Future
Research
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